Ownership and insider activity for PepGen Inc. (PEPG): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
PepGen Inc., a clinical-stage biotechnology company, develops oligonucleotide therapeutics for the treatment of severe neuromuscular and neurologic diseases in the United States. The company engages in the development of PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 2 clinical trial for the treatment of myotonic dystrophy type 1; and FREEDOM2-DM1, which is in Phase 2 for the treatment of myotonic dystrophy type 1.
Price
| Price | $2.90 |
| Market Cap | $201M |
| Exchange | NASDAQ |
| Country | US |
Balance Sheet (10y)
| Year | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $3.5M | $9.8M | $132.9M | $181.8M | $80.8M | $49.4M | $60.5M |
| Short-term Investments | 0 | 0 | 0 | 0 | $29.6M | $70.8M | $87.9M |
| Receivables | $230000 | $407000 | $4.7M | $58000 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Assets | $3.8M | $10.3M | $140.0M | $186.1M | $112.7M | $123.8M | $151.0M |
| Property, Plant & Equipment | $419000 | $323000 | $636000 | $29.9M | $28.4M | $25.1M | $21.0M |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Assets | $4.2M | $10.6M | $143.6M | $217.4M | $143.1M | $150.9M | $173.9M |
| Accounts Payable | $141000 | $721000 | $3.2M | $1.4M | $1.0M | $1.8M | $822000 |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Liabilities | $326000 | $838000 | $10.3M | $18.8M | $17.5M | $16.7M | $12.6M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 | 0 | $13.8M |
| Total Liabilities | $326000 | $868000 | $10.5M | $37.8M | $34.6M | $32.3M | $26.5M |
| Retained Earnings | -$2.4M | -$6.5M | -$33.8M | -$102.9M | -$181.5M | -$271.5M | -$361.1M |
| Total Equity | $3.9M | $9.8M | $133.1M | $179.6M | $108.4M | $118.6M | $147.4M |
| Total Debt | 0 | 0 | 0 | $24.5M | $20.1M | $18.7M | $17.0M |
| Net Debt | -$3.5M | -$9.8M | -$132.9M | -$157.2M | -$90.3M | -$101.5M | -$131.5M |
| Working Capital | $3.4M | $9.5M | $129.7M | $167.3M | $95.1M | $107.1M | $138.3M |
Financial Health
| Debt / Equity | 0.13 |
| Current Ratio | 13.36 |
Profitability
| Return on Equity | -51.01% |
| Return on Invested Capital | -56.21% |
| Return on Assets | -50.88% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: ALEC · APLT · CRBP · CRDF · CYBN · ELTX · FATE
Explore sector: Healthcare · Biotechnology
More sections of PEPG: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks